Astrazeneca (AZN) signed a three-year licensing agreement with Owkin to develop biopharma AI agents using Owkin's K Pro platform for drug development and decision-making, Owkin said Wednesday.
Under the agreement, Owkin said it will develop and deploy AI agents within AstraZeneca's IT systems and workflows to support competitive intelligence and data-driven decision making across the biopharma value chain.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments